Benzinga | Nov 10, 2020 08:29AM EST

Jefferies Initiates Coverage On Tarsus Pharmaceuticals with Buy Rating, Announces Price Target of $35

Jefferies initiates coverage on Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy rating and announces Price Target of $35.